pipobroman has been researched along with Primary Myelofibrosis in 11 studies
Pipobroman: An antineoplastic agent that acts by alkylation.
pipobroman : An N-acylpiperazine that is piperazine in which each of the nitrogens has been acylated by a 3-bromopropionoyl group. An anti-cancer drug.
Primary Myelofibrosis: A de novo myeloproliferation arising from an abnormal stem cell. It is characterized by the replacement of bone marrow by fibrous tissue, a process that is mediated by CYTOKINES arising from the abnormal clone.
| Excerpt | Relevance | Reference |
|---|---|---|
| "From 1968 to 1993, 179 newly diagnosed patients with polycythemia vera (PV) were enrolled in a prospective study using pipobroman as first chemotherapy." | 9.10 | Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy. ( Bernard, JF; Bruno, F; Gardin, C; Kiladjian, JJ; Renoux, M, 2003) |
| "Between 1971 and 1981, 74 patients with polycythemia vera were treated with pipobroman using a high-dose induction, low-dose maintenance regimen." | 7.66 | Pipobroman therapy of polycythemia vera. ( Duhamel, G; Gorin, NC; Najman, A; Parlier, Y; Stachowiak, J, 1982) |
| "Pipobroman (PB) is a neutral amide of piperazine with a chemical structure close to that of alkylating agents, although the exact mechanism of action of PB has not been demonstrated." | 6.42 | Treatment of polycythemia vera and essential thrombocythemia: the role of pipobroman. ( Lazzarino, M; Passamonti, F, 2003) |
| "An analysis of the risk of progression towards leukemia, carcinoma and myelofibrosis was performed in 93 patients treated by 32P alone (PVSG protocols) since 1970-1979, 395 patients over the age of 65 years treated by 32P with or without maintenance therapy using hydroxyurea (French protocol) since 1980-1994, and 202 patients under the age of 65 treated by either hydroxyurea or pipobroman since 1980." | 6.18 | Risk of leukaemia, carcinoma, and myelofibrosis in 32P- or chemotherapy-treated patients with polycythaemia vera: a prospective analysis of 682 cases. The "French Cooperative Group for the Study of Polycythaemias". ( Dresch, C; Echard, M; Goguel, A; Grange, MJ; Lejeune, F; Najean, Y; Rain, JD, 1996) |
| "Acute myeloid leukaemia, myelofibrosis and solid tumours occurred in three, two and seven patients with a 10-year cumulative risk of 3%, 2% and 7% respectively." | 5.31 | Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis. ( Astori, C; Baratè, C; Bernasconi, P; Brusamolino, E; Canevari, A; Cazzola, M; Corso, A; Lazzarino, M; Malabarba, L; Orlandi, E; Pascutto, C; Passamonti, F, 2002) |
| "From 1968 to 1993, 179 newly diagnosed patients with polycythemia vera (PV) were enrolled in a prospective study using pipobroman as first chemotherapy." | 5.10 | Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy. ( Bernard, JF; Bruno, F; Gardin, C; Kiladjian, JJ; Renoux, M, 2003) |
| " Randomized studies have shown that the risk of thrombosis was significantly reduced in ET with the use of hydroxyurea (HU) and in PV with the use of chlorambucil or 32P." | 4.80 | Treatment of polycythaemia vera and essential thrombocythaemia. ( Silverstein, MN; Tefferi, A, 1998) |
| "Between 1971 and 1981, 74 patients with polycythemia vera were treated with pipobroman using a high-dose induction, low-dose maintenance regimen." | 3.66 | Pipobroman therapy of polycythemia vera. ( Duhamel, G; Gorin, NC; Najman, A; Parlier, Y; Stachowiak, J, 1982) |
| "Pipobroman (PB) is a neutral amide of piperazine with a chemical structure close to that of alkylating agents, although the exact mechanism of action of PB has not been demonstrated." | 2.42 | Treatment of polycythemia vera and essential thrombocythemia: the role of pipobroman. ( Lazzarino, M; Passamonti, F, 2003) |
| "Risk of thrombosis is higher in JAK2-mutated ET." | 1.51 | Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. ( Barbui, T; Tefferi, A, 2019) |
| "Cases (n = 647) were patients with second cancer (SC: carcinoma, non-melanoma skin cancer, hematological second cancer, and melanoma) and controls (n = 1234) were patients without SC, matched with cases for sex, age at MPN diagnosis, date of MPN diagnosis, and MPN disease duration." | 1.51 | Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study. ( Alvarez-Larran, A; Angona, A; Barbui, T; Beggiato, E; Benevolo, G; Bertolotti, L; Betti, S; Bonifacio, M; Cacciola, R; Carli, G; Carobbio, A; Casetti, IC; Cattaneo, D; De Stefano, V; Delaini, F; Di Veroli, A; Elli, EM; Erez, D; Finazzi, G; Fox, ML; Ghirardi, A; Gomez, M; Griesshammer, M; Guglielmelli, P; Iurlo, A; Lunghi, F; Marchetti, M; Masciulli, A; McMullin, MF; Palandri, F; Palova, M; Patriarca, A; Perez-Encinas, M; Recasens, V; Rumi, E; Scaffidi, L; Stephenson, C; Tieghi, A; Vannucchi, AM; Vianelli, N; Wille, K, 2019) |
| "Acute myeloid leukaemia, myelofibrosis and solid tumours occurred in three, two and seven patients with a 10-year cumulative risk of 3%, 2% and 7% respectively." | 1.31 | Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis. ( Astori, C; Baratè, C; Bernasconi, P; Brusamolino, E; Canevari, A; Cazzola, M; Corso, A; Lazzarino, M; Malabarba, L; Orlandi, E; Pascutto, C; Passamonti, F, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (18.18) | 18.7374 |
| 1990's | 2 (18.18) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tefferi, A | 2 |
| Barbui, T | 2 |
| Andriani, A | 1 |
| Elli, E | 1 |
| Trapè, G | 1 |
| Villivà, N | 1 |
| Fianchi, L | 1 |
| Di Veroli, A | 2 |
| Niscola, P | 1 |
| Centra, A | 1 |
| Anaclerico, B | 1 |
| Montanaro, G | 1 |
| Martini, V | 1 |
| Aroldi, A | 1 |
| Carmosino, I | 1 |
| Voso, MT | 1 |
| Breccia, M | 1 |
| Montanaro, M | 1 |
| Foà, R | 1 |
| Latagliata, R | 1 |
| Ghirardi, A | 1 |
| Masciulli, A | 1 |
| Carobbio, A | 1 |
| Palandri, F | 1 |
| Vianelli, N | 1 |
| De Stefano, V | 1 |
| Betti, S | 1 |
| Iurlo, A | 1 |
| Cattaneo, D | 1 |
| Delaini, F | 1 |
| Bonifacio, M | 1 |
| Scaffidi, L | 1 |
| Patriarca, A | 1 |
| Rumi, E | 1 |
| Casetti, IC | 1 |
| Stephenson, C | 1 |
| Guglielmelli, P | 1 |
| Elli, EM | 1 |
| Palova, M | 1 |
| Bertolotti, L | 1 |
| Erez, D | 1 |
| Gomez, M | 1 |
| Wille, K | 1 |
| Perez-Encinas, M | 1 |
| Lunghi, F | 1 |
| Angona, A | 1 |
| Fox, ML | 1 |
| Beggiato, E | 1 |
| Benevolo, G | 1 |
| Carli, G | 1 |
| Cacciola, R | 1 |
| McMullin, MF | 1 |
| Tieghi, A | 1 |
| Recasens, V | 1 |
| Marchetti, M | 1 |
| Griesshammer, M | 1 |
| Alvarez-Larran, A | 1 |
| Vannucchi, AM | 1 |
| Finazzi, G | 1 |
| Stein, BL | 1 |
| Moliterno, AR | 1 |
| Tiu, RV | 1 |
| Kiladjian, JJ | 1 |
| Gardin, C | 1 |
| Renoux, M | 1 |
| Bruno, F | 1 |
| Bernard, JF | 1 |
| Passamonti, F | 2 |
| Lazzarino, M | 2 |
| Najman, A | 1 |
| Stachowiak, J | 1 |
| Parlier, Y | 1 |
| Gorin, NC | 1 |
| Duhamel, G | 1 |
| Najean, Y | 1 |
| Rain, JD | 1 |
| Dresch, C | 1 |
| Goguel, A | 1 |
| Lejeune, F | 1 |
| Echard, M | 1 |
| Grange, MJ | 1 |
| Silverstein, MN | 1 |
| Malabarba, L | 1 |
| Orlandi, E | 1 |
| Pascutto, C | 1 |
| Brusamolino, E | 1 |
| Astori, C | 1 |
| Baratè, C | 1 |
| Canevari, A | 1 |
| Corso, A | 1 |
| Bernasconi, P | 1 |
| Cazzola, M | 1 |
| Böhnel, J | 1 |
| Stacher, A | 1 |
4 reviews available for pipobroman and Primary Myelofibrosis
| Article | Year |
|---|---|
Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options.
Topics: Clinical Trials, Phase III as Topic; Combined Modality Therapy; Cost of Illness; Disease Progression | 2014 |
Treatment of polycythemia vera and essential thrombocythemia: the role of pipobroman.
Topics: Abortion, Spontaneous; Acute Disease; Alkylating Agents; Female; Humans; Leukemia, Myeloid; Middle A | 2003 |
Risk of leukaemia, carcinoma, and myelofibrosis in 32P- or chemotherapy-treated patients with polycythaemia vera: a prospective analysis of 682 cases. The "French Cooperative Group for the Study of Polycythaemias".
Topics: Actuarial Analysis; Acute Disease; Carcinoma; Cause of Death; Disease Progression; Follow-Up Studies | 1996 |
Treatment of polycythaemia vera and essential thrombocythaemia.
Topics: Adult; Aged; Aspirin; Chlorambucil; Disease Progression; Female; Hemorrhage; Humans; Hydroxyurea; In | 1998 |
2 trials available for pipobroman and Primary Myelofibrosis
| Article | Year |
|---|---|
Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy.
Topics: Actuarial Analysis; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Cause of Deat | 2003 |
Risk of leukaemia, carcinoma, and myelofibrosis in 32P- or chemotherapy-treated patients with polycythaemia vera: a prospective analysis of 682 cases. The "French Cooperative Group for the Study of Polycythaemias".
Topics: Actuarial Analysis; Acute Disease; Carcinoma; Cause of Death; Disease Progression; Follow-Up Studies | 1996 |
6 other studies available for pipobroman and Primary Myelofibrosis
| Article | Year |
|---|---|
Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
Topics: Adult; Aspirin; Bone Marrow; Busulfan; Disease Management; Disease Progression; Hemorrhage; Humans; | 2019 |
Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Blast Crisis; Female; Humans; Hydroxyurea; Leuke | 2019 |
Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study.
Topics: Antineoplastic Agents; Case-Control Studies; Humans; Hydroxyurea; Neoplasms, Second Primary; Nitrile | 2019 |
Pipobroman therapy of polycythemia vera.
Topics: Drug Evaluation; Female; Humans; Male; Pipobroman; Polycythemia Vera; Primary Myelofibrosis | 1982 |
Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis.
Topics: Adult; Aged; Aged, 80 and over; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Male; Middle A | 2002 |
[On the effect of a new cytostatic drug in chronic myeloses and polycythemias].
Topics: Animals; Antineoplastic Agents; Bromine; Chronic Disease; Erythrocyte Count; Erythropoiesis; Female; | 1968 |